The American Journal of Managed Care4m
Survival Differences Seen Among Children With Retinoblastoma in European Countries
Despite the incidence of retinoblastoma remaining consistent throughout Europe, different countries had differing rates of ...
The American Journal of Managed Care45m
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
The American Journal of Managed Care2h
Navigating the Complexities of Cancer Care: Cannabis and Cost Considerations
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care4h
In Cancer Care, Innovation Comes at a Cost
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care2h
Dr Maxine Dexter: Physician Voices are Crucial to Public Health
During CHEST 2024, Maxine Dexter, MD, Kaiser Permanente, discussed her belief in the vital role of physicians in public health advocacy, drawing from her legislative work on issues as a former Oregon ...
The American Journal of Managed Care23h
Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care1d
In Wake of Express Scripts Suit, FTC Takes On 3 Largest PBMs
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care2d
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care2d
FDA Approves Imuldosa, a Fifth Biosimilar to Stelara
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
The American Journal of Managed Care3d
In Lower-Risk MDS, Genomic Dynamics Heighten Likelihood of Treatment
The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic ...
The American Journal of Managed Care2d
FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer
Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after ...
The American Journal of Managed Care3d
NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials
An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of ...